STOCK TITAN

60 Degrees Pharmaceuticals, Inc. Warrant - SXTPW STOCK NEWS

Welcome to our dedicated page for 60 Degrees Pharmaceuticals Warrant news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharmaceuticals Warrant stock.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Recent achievements include their Chief Executive Officer, Geoff Dow, PhD, planning a clinical trial to study the use of tafenoquine in treating human babesiosis, a tick-borne disease. The Company has been focused on developing new medicines for rare infectious diseases and collaborating with renowned research organizations in the U.S., Australia, and Singapore.

Financially, 60 Degrees Pharmaceuticals recently reported results for the first fiscal quarter of 2024, showcasing a strong commitment to advancing treatments for infectious diseases.

Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) and Tufts Medical Center have signed a Patent License Agreement to develop and commercialize tafenoquine for babesiosis treatment and prevention. The agreement establishes joint patent ownership, with 60 Degrees leading global commercialization efforts and holding exclusive rights. Tufts MC will receive royalties on net sales while retaining research rights. The collaboration aims to address an unmet medical need, as tafenoquine could potentially become the first prophylaxis available for babesiosis, a tick-borne disease affecting red blood cells. The agreement follows initial research collaboration between both organizations, resulting in U.S. Provisional Patent Application No. 63/461,060.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has expanded its tafenoquine clinical trial for babesiosis to Brigham and Women's Hospital in Boston. The double-blind, placebo-controlled study will evaluate tafenoquine combined with standard treatment for hospitalized babesiosis patients. The trial is also ongoing at Tufts Medical Center, Yale University, and Rhode Island Hospital.

The study aims to recruit 24-33 patients in summer 2025, with an interim analysis expected in early 2026. The main endpoints are time to sustained clinical resolution of symptoms and molecular cure. Recent case studies suggest tafenoquine with standard care shows high cure rates in immunosuppressed patients with relapsing babesiosis. The company estimates the total accessible market through December 2035 could exceed 400,000 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.47%
Tags
-
Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q3 2024 financial results showing significant year-over-year growth. Sales revenue increased 164% to $135 thousand, driven by a 140% increase in ARAKODA® pharmacy deliveries. The company achieved a gross profit of $24 thousand, compared to a $20 thousand loss in Q3 2023. However, operating expenses rose to $2.16 million, and net loss was $2.27 million. A $4 million private placement was completed at $1.38 per share. Key business developments included granting University of Kentucky reference rights for ARAKODA®, securing a U.S. Army contract, and advancing clinical trials for babesiosis treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
186.92%
Tags
Rhea-AI Summary

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has launched a nine-month promotional pilot for ARAKODA® (tafenoquine), an antimalarial medication. The pilot aims to increase brand awareness and utilization through virtual sales outreach and a co-pay assistance program. ARAKODA is the only FDA-approved prophylactic therapy that protects against all malaria stages, offering a convenient weekly dosing schedule.

The program includes virtual sales representatives conducting outreach to promote the co-pay program and boost sales. Data generated will inform the company on customer demographics, pricing, prescription trends, and guide future promotional efforts. This initiative precedes a planned expanded U.S. sales effort in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.02%
Tags
none
-
Rhea-AI Summary

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has closed a $4 million private placement of common stock and warrants. The offering included 2,898,551 shares (or equivalents) at $1.38 per share, with accompanying series A and B warrants. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the proceeds for working capital, general operations, commercialization of Arakoda, and R&D. The securities were offered under Section 4(a)(2) of the Securities Act and have not been registered, limiting their sale in the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
private placement
-
Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a $4 million private placement priced at-the-market under Nasdaq rules. The company will issue and sell 2,898,551 shares of common stock (or equivalents) at $1.38 per share, along with series A and short-term series B warrants. The warrants will have an exercise price of $1.38 per share, with series A expiring in five years and series B in 18 months from stockholder approval.

H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around September 5, 2024. 60P plans to use the net proceeds for working capital, general operations, Arakoda commercialization, and research and development. The securities are being offered under Section 4(a)(2) of the Securities Act and have not been registered, limiting their sale in the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
private placement
Rhea-AI Summary

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a company focused on developing new medicines for infectious diseases, has regained compliance with Nasdaq's minimum bid price requirement. The company received written notice from Nasdaq on August 26, 2024, confirming its compliance with the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2).

60P had been notified of non-compliance on February 27, 2024, as its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. To regain compliance, the company needed to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This was achieved between August 12, 2024, and August 23, 2024, with the company's closing price reaching $1.81 on August 23, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q2 2024 financial results, showing significant growth in net product revenues. Key highlights include:

- Net product revenues doubled year-over-year to $125,000
- Sequential quarter-over-quarter revenue growth of 18.3%
- Gross profit improved from ($124,000) loss to $35,000 gain
- ARAKODA® pharmacy deliveries increased by 288%
- Operating expenses rose to $4.22 million, impacted by a non-recurring R&D charge
- Net loss widened to $4.29 million or ($4.23) per share

The company also reported progress in its clinical trials, with the first patient enrolled in a tafenoquine study for Babesiosis at Tufts Medical Center. Additionally, the FDA granted Orphan Drug Designation for tafenoquine in acute babesiosis treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has granted the University of Kentucky a right of reference to its NDA for ARAKODA® (tafenoquine), an FDA-approved anti-malarial. This allows the FDA to review ARAKODA's data when evaluating protocols for the university's upcoming Phase IIb study of SJ733, an oral ATP4 inhibitor of Plasmodium, combined with tafenoquine for vivax malaria treatment.

The study, funded by the Global Health Innovative Technology Fund, aims to evaluate the safety, tolerability, and pharmacokinetics of this single-dose combination. It potentially offers a significant advancement in malaria treatment, especially in areas with chloroquine-resistant P. vivax. 60 Degrees Pharma will supply tafenoquine and placebos for the trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a 1:12 reverse stock split of its common stock, effective August 12, 2024. This move is primarily aimed at complying with Nasdaq's $1.00 minimum bid price requirement to maintain its listing. The stock will continue trading under the symbol 'SXTP' with a new CUSIP number 83006G203. The split will automatically convert 12 current shares into one new share, with proportional adjustments made to equity awards, warrants, and convertible notes. No fractional shares will be issued, and all fractions will be rounded up. The split won't alter the par value or authorized number of shares, and stockholders' percentage interests will remain unchanged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW)?

The current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW) is $0.039 as of December 20, 2024.

What is 60 Degrees Pharmaceuticals focused on?

60 Degrees Pharmaceuticals is focused on developing new medicines for the prevention and treatment of infectious diseases.

What recent achievement did 60 Degrees Pharmaceuticals announce?

60 Degrees Pharmaceuticals announced a clinical trial to study the use of tafenoquine in treating human babesiosis.

Who is leading the efforts at 60 Degrees Pharmaceuticals?

Geoff Dow, PhD, is the Chief Executive Officer of 60 Degrees Pharmaceuticals.

60 Degrees Pharmaceuticals, Inc. Warrant

Nasdaq:SXTPW

SXTPW Rankings

SXTPW Stock Data

1.86M
Medicinal and Botanical Manufacturing
Pharmaceutical Preparations
United States of America
WASHINGTON